Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

At CTS Nordics, Arnaud Dourlens explained how Sanofi has engaged between clinical operations and supply teams earlier to ...

Dash Solutions has introduced dashClinical, a payment solution that provides real-time, secure payments to clinical trial ...

BridgeBio’s stock was up after it announced the Phase III trial met its endpoints. Image credit: saepul_bahri / Shutterstock.com. BridgeBio Pharma will seek US approval of its limb-girdle muscular ...

The data was announced during the 2025 North American Menopause Society (NAMS) Annual Meeting. Image credit: shisu_ka / Shutterstock.com. Entera Bio’s osteoporosis candidate for postmenopausal women ...

Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...

Electra is assessing ELA026 for haematologic cancers, following promising initial clinical data. Credit: Motortion Films / Shutterstock.com. Electra Therapeutics has raised $183m in an oversubscribed ...

Medtronic plans to use data from the ADAPT-PD trial to support the Percept PC’s aDBS global regulatory filing. Image credit: JHVEPhoto / Shutterstock. Medtronic has published preliminary data from a ...

Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli Lilly’s Zepbound (tirzepatide) in a ...

Lilly is continuing with its goal of submitting for approval of orforglipron in obesity by the end of 2025, and in type 2 diabetes in 2026. Image credit: Tada Images / Shutterstock.com Eli Lilly’s ...